<SEC-DOCUMENT>0001193125-25-243950.txt : 20251021
<SEC-HEADER>0001193125-25-243950.hdr.sgml : 20251021
<ACCEPTANCE-DATETIME>20251020200048
ACCESSION NUMBER:		0001193125-25-243950
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20251020
FILED AS OF DATE:		20251021
DATE AS OF CHANGE:		20251020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		251405162

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d62294d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as October 20, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#8217;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#8220;Yes&#8221; is marked, indicated below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d62294dex991.htm">Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October 20, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d62294dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g62294g1020165050929.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Primary Endpoint Met in <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> Phase II Evaluating Neoadjuvant
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Novel combination including eftilagimod alfa (efti) in neoadjuvant setting drives 51.5% tumour hyalinization/fibrosis in
patients with soft tissue sarcoma (p&lt;0.001) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">High level of tumour hyalinization/fibrosis, achieved across multiple STS subtypes, over
<FONT STYLE="white-space:nowrap">3-fold</FONT> greater than historical results from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> radiotherapy alone </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Arial; font-size:10pt">Data from investigator-initiated Phase II selected for Proffered Paper oral presentation </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>SYDNEY, AUSTRALIA &#8211; October, 20, 2025 &#8211;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#8220;Immutep&#8221; or &#8220;the
Company&#8221;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces positive data from the <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> Phase II trial were shared in a Proffered Paper oral
presentation by Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, at the 2025 European Society of Medical Oncology (ESMO) Congress in Berlin, Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The investigator-initiated Phase II study evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) met the primary endpoint and significantly exceeded the study&#8217;s prespecified 35% tumour
hyalinization/fibrosis. In the evaluable patient population (N=38), the novel combination with efti reached a median 51.5% tumour hyalinization/fibrosis (p&lt;0.001). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">This impressive outcome, over three times greater than 15% from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> radiotherapy alone based on historical data, may hold significance in terms of future outcomes as tumour hyalinization/fibrosis serves as an early
surrogate endpoint correlated with enhanced overall survival and recurrence-free survival in STS patients.<SUP STYLE="font-size:75%; vertical-align:top">1,2</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">These promising results were achieved across multiple STS subtypes and the study proved a very good safety profile for the therapy, with only one grade <FONT
STYLE="font-family:Times New Roman">&#8805;</FONT>3 toxicity related to immunotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Dr.</B><B></B><B>&nbsp;Katarzyna Kozak, said:
</B>&#8220;The novel combination with neoadjuvant efti has significantly exceeded the originally established target for the trial&#8217;s primary endpoint in resectable soft tissue sarcoma. These outcomes achieved in a diverse population of multiple
STS subtypes further substantiate the hypothesis that efti&#8217;s unique stimulation of antigen-presenting cells, resulting in a robust adaptive and innate immune response, contributes to modifying the immunosuppressed tumour microenvironment and
achieving notable anti-cancer efficacy in soft tissue sarcomas. We hope these findings can help pave a path to a new therapeutic option for the substantial unmet medical need in this challenging indication.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify"><B>Marc Voigt, CEO of Immutep, noted:</B> &#8220;We sincerely&nbsp;thank&nbsp;the principal investigators leading this study, as well as the patients
and their families for taking part in this important trial. There is a significant unmet medical need for novel therapies in STS that have the potential to provide better outcomes for patients than the current standard of care radiotherapy.&#8221;
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g62294g1020165051023.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237
889 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">STS is an orphan disease with high unmet medical need and a poor prognosis for patients. The incidence
of STS varies in different regions globally. In the United States, the number of new STS cases in 2025 is estimated to be ~13,520 with ~5,420 deaths, according to the American Cancer Society.<SUP STYLE="font-size:75%; vertical-align:top">3</SUP>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> study has been primarily funded with a grant from the Polish government awarded by the
Polish Medical Research Agency program. For more information on <FONT STYLE="white-space:nowrap">EFTISARC-NEO,</FONT> visit clinicaltrials.gov (NCT06128863). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">The presentation slides can be found on the Posters&nbsp;&amp; Publications page of Immutep&#8217;s website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>About Eftilagimod Alfa (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Efti is a novel immunotherapy
that directly activates antigen-presenting cells or APCs (e.g. dendritic cells, monocytes) via the MHC Class&nbsp;II pathway to fight cancer. As an MHC Class&nbsp;II agonist, its activation of APCs engages the adaptive and innate immune system to
initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as generating important <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> signals&nbsp;&amp; cytokines that further boost the immune
system&#8217;s ability to combat cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Efti is under evaluation for a variety of solid tumours including
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) in a pivotal Phase III trial called <FONT STYLE="white-space:nowrap">TACTI-004</FONT> <FONT STYLE="white-space:nowrap">(KEYNOTE-F91),</FONT> as well as head and neck squamous
cell carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its favourable safety profile enables various combinations like with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy,
radiotherapy, and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Immutep is a late-stage biotechnology company
developing novel immunotherapies for cancer and autoimmune disease<I>.</I> The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT><B> </B><FONT
STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#8217;s</FONT> ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Arial; " ALIGN="justify"><I>Schaefer IM et al. Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment
of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score. Int J Radiat Oncol Biol Phys. 2017 Jun <FONT STYLE="white-space:nowrap">1;98(2):375-383.</FONT> doi: 10.1016/j.ijrobp.2017.02.087.
Epub 2017 Feb 24. PMID: 28463157. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Arial; " ALIGN="justify"><I>Rao SR et al. Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is
associated with improved survival in patients with soft-tissue sarcoma. Cancer Med. 2022 <FONT STYLE="white-space:nowrap">Jan;11(1):194-206.</FONT> doi: 10.1002/cam4.4428. Epub 2021 Nov 27. PMID: 34837341; PMCID: PMC8704179.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Arial; " ALIGN="justify"><I>American Cancer Society statistics:
<FONT STYLE="white-space:nowrap">https://www.cancer.org/cancer/types/soft-tissue-sarcoma/about/key-statistics.html</FONT> </I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><I>KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">Eleanor Pearson,
Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">+61 2 9066 4071; <U>eleanor.pearson@sodali.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g62294g1020165051023.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237
889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">Chris Basta, VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial">+1 (631) 318 4000;
<U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="justify">This announcement was authorised for release by the CEO of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g62294g1020165051023.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Arial" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia; ABN: 90 009 237
889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g62294g1020165050929.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62294g1020165050929.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ +,# 2(  A$! Q$!_\0
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M:W\5A/>P1W4W^KB9P&;/3CWJ[0%PHHHH **** "BBB@ HHHH **** "BBB@
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MH_AY]+U%[IIU?<A7 &.I'^%)/<TG"3E!I;%/QO\ ZBS^K?\ LM37W_(B1_\
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M3'X'%:7BWS7,^6:@Z=C;N5+_  4 49/V-#^3 U!\'94.@W\(8>8MSN*]P"H
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HTVTTBPBL;*+RK>+.Q-Q.,DD\GGJ35NDW=W*BK12"BBBD4%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g62294g1020165051023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62294g1020165051023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  @ !\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V#Q#XA&E@
M06X#7+#))Z(/\:X>XOKN^D_?SO(6/ 9N/_K5H1:E82:C?7&I6SW"S9\O&,I_
MGCGVK9T3PK93VL=W<R/.LF&C494;??WK16B>9+GKR]UZ&1IBZU%J1M+*0^9&
M-S+O^0#W[5V>E:F;T2P7$8BO(#MECS^H]JY_58V\+3_:=/&6NV(+2_-LQSM'
MU]_2L;3=7F@UHW\SEG?/F=MV1T^G3\J&KE0G[&7*_P#@%/4+4V=_-;D$;'(&
M?3UKJ]"\0V]EHT,6H%H]I*1'83O4=_PZ5=\0^'QJ@$\!"W*C!!Z./\:Y36Y+
M^>6,WEIY!B78,*<&C22)<98>3:-#5]:L-<N8;=_-@MHV)$_?./[OI67H^G_V
MCJ@MURR?,=V.PZ'^7YU%9Z5>WSJL%N[ _P 6.!^-=[H6BII%N<D/._WV';V%
+-M104X3KSYI(_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
